Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemchymal in Polyglutamine Spinocerebellar Ataxia
NCT02540655Phase 2Completed
- Sponsor
- Steminent Biotherapeutics
- Start
- Sep 2015
- Primary completion
- Feb 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Spinocerebellar Ataxia Type 2 (SCA2) and spinocerebellar ataxia type 3 (SCA3) comparing Stemchymal with Vehicle (2 arms). Primary endpoint: Scale for the Assessment and Rating of Ataxia at 14 months. Started Sep 2015; status: completed.
02
Drugs
Stemchymal
03
Conditions
Spinocerebellar Ataxia Type 2 (SCA2)spinocerebellar ataxia type 3 (SCA3)
Beyond the preview
Go deeper on NCT02540655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540655.